Novartis Reports $2.2bn Hit From Drug Trial Setbacks, but Lifts Guidance
6 Articles
6 Articles
The pharmaceutical company has to write off nearly two billion dollars because a potential new product did not show the desired effect. The company's CEO plays down the failure. However, many market observers are skeptical.
Novartis suffers with $2.2 bi on failed test orders, but high profit projection; understand the effects
The operating profit of Swiss pharmaceuticals fell 61% in the third quarter, damaged by higher research and development costs
Novartis recorded about $2.2 billion (R$ 11.88 billion) in expenses related to two medicines that failed in advanced phase studies last month, even though it increased its profit projections for the whole year on Tuesday (27). Read more (10/27/2026)
Novartis registered about $2.2 billion in expenses related to two medicines that...
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
